2 citations
,
July 2025 in “Advances in Therapy” In this study, patients with more severe self-reported hair loss and emotional or social limitations experienced lower quality of life and greater work productivity impairment, with even moderate hair loss causing significant well-being and daily activity impacts.
March 2025 in “Meditsinskiy sovet = Medical Council” This study reviewed literature and assessed clinical data on treating alopecia areata linked with atopic diseases, finding that therapies like dupilumab, phototherapy, and JAK inhibitors may address overlapping symptoms, suggesting a focus on reducing pharmacological burden and enhancing quality of life.
10 citations
,
October 2024 in “Dermatology Practical & Conceptual” This study found that dupilumab's effects on alopecia areata varied depending on patients' immune profiles, with Th2-skewed females seeing improvements and Th1-driven males experiencing worsening.
91 citations
,
May 2023 in “Journal of Cutaneous Medicine and Surgery” Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
34 citations
,
November 2022 in “Clinical and Experimental Dermatology” This study found that individuals with AA have a higher incidence of atopic and autoimmune conditions, suggesting both Th1 and Th2 immune responses may play a role in its development.
4 citations
,
November 2022 in “Frontiers in Medicine” This study found that people with alopecia areata have a higher likelihood of experiencing anxiety and depression, and a moderate negative impact on their quality of life compared to healthy individuals.
11 citations
,
January 2022 in “Journal der Deutschen Dermatologischen Gesellschaft” This review discusses current and emerging therapies for alopecia areata, highlights the challenges in managing this chronic disease, and emphasizes the importance of addressing its psychosocial impacts; it reports no new clinical results.
11 citations
,
November 2021 in “BMJ Open” This study reviews the epidemiology of alopecia areata in the UK, focusing on its links to mental health comorbidities, autoimmune/atopic associations, and common infection incidences.
31 citations
,
July 2021 in “ImmunoTargets and therapy” This review compiles current evidence on the molecular mechanisms, etiologies, and targeted immunotherapies for alopecia areata and reports no new experimental results, emphasizing the need for further research to manage the disease.
57 citations
,
March 2021 in “International Journal of Molecular Sciences” This study found that type 2 immunity may play a role in the development of alopecia areata in patients with extrinsic atopic dermatitis, indicating different immunological states compared to non-atopic patients.
23 citations
,
November 2020 in “Central-European Journal of Immunology/Central European Journal of Immunology” This review explores the autoimmune hypothesis of alopecia areata and the possible genetic and melanogenesis-associated autoantigens, but reports no new clinical findings.
100 citations
,
July 2018 in “Journal of The American Academy of Dermatology” This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.
